key: cord-0738984-cy08wsp0 authors: Rahimi, Farid; Abadi, Amin Talebi Bezmin title: Emergence of the Delta Plus variant of SARS-CoV-2 in Iran date: 2021-09-03 journal: Gene Rep DOI: 10.1016/j.genrep.2021.101341 sha: 2ed388600248e0a150c7d5daf772f468bac1e8ad doc_id: 738984 cord_uid: cy08wsp0 nan was argued to be taken cautiously (6) . Following the emergence of the variants, many European countries closed their borders to the UK goods or visitors. By July 2021, the WHO website Tracking SARS-CoV-2 Variants, published an updated list of the viral variants-variants of concern and variants of interest (7)-while renaming the variants was suggested in January 2021 (8). The variants of concern include the Alpha (B. The UK variant (Alpha, B.1.1.7) has been reported in the Netherlands, Sweden, Denmark, Norway, Poland, Hungry, Iceland, Greece, Colorado, Australia, and other countries (https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b- Iran is one of the frontiers against the COVID-19 pandemic in the Middle East. Since 24 January 2021, the COVID-19 incidence in Iran has risen slowly with an increasing fatality rate, mostly in the North (11). In late June 2021, new incidence peaks emerged in the Southern states and disseminated to other states (12). By mid-August, officials recorded a high fatality rate of 600 daily. These figures deeply concerned the authorities while they strived to understand the origin and spread of the variants to avoid potentially higher transmission or fatalities (6) . The cartographic spread of the high case numbers spreading from the south to the north and finally throughout Iran as documented by the Iranian Health Ministry (https://app.mask.ir/map) shows the directional viral spread with time ( Figure 1 ). Experts are generally optimistic that the present vaccines could effectively target the variants (4), but the optimism could change with accumulating epidemiological and serological evidence (16) . AstraZeneca indicated that 6-9 months' is required to produce an effective vaccine against the new variants (17); however, comparing the humoral immune responses with T-cell responses is also important for understanding how vaccinated subjects fight the variants. Recently, the Pfizer CEO Albert Bourla indicated that a booster vaccine dose a year after initial full vaccination may be needed (18) . Worryingly, the durability of antibody responses in fully vaccinated or semi-vaccinated subjects is still not fully understood. Because SARS-CoV-2 has undergone genetic evolution 16 months after its global dissemination, flexible public-health policies and specific testing regimes are mandatory to effectively tackle the evolving variants. When writing this letter, no validated diagnostic PCR test was available to distinguish between the variants. However, a preprinted RT-PCR method can detect some variants (19) . Therefore, the corresponding proportions of the new cases should be determined and documented cautiously before widespread Pfizer or BioNTech vaccinations. Although the B.1.1.7 variant is reportedly susceptible to the two vaccines, emerging spikeprotein mutations could alter its conformation or epitopes, probably causing vaccine failures (20) . Thus, strict traveling bans, strict quarantine of international travelers, contact-tracing, testing campaigns, restricting private or public gatherings, mass vaccinations, physical distancing, respiratory and hand hygiene, and face-masking are still pertinent mainstay J o u r n a l P r e -p r o o f Journal Pre-proof countermeasures during the pandemic evolution. Iran exemplifies (Figure 1, 2) how Delta plus or other variants could spread fast to many regions. Meanwhile, an overwhelmed healthcare taskforce, combating the pandemic and caring for the patients affected by the variants, is further challenged by: 1) a high chance of secondary, multidrug-resistant bacterial infections 2) emotional, mental, and physical fatigue 3) high fatalities because of seasonal flu, secondary infections, or comorbidities. In conclusion, Delta plus may not be the last SARS-CoV-2 variant. Effective policies expectedly better control the pandemic worldwide. Urgent national and international vaccinations may guarantee the future defeat of SARS-CoV-2, and sophisticated information on the evolving viral genome will facilitate defining and implementing better countermeasures. A genomic surveillance, like the COG-UK, is required internationally to coordinate documentation of the variants because genomic sequencing is not readily available in many low-income and middle-income countries. A timeline of COVID-19 developments in 2020: AJMC; 2020 UK PM claims Britain's 'super-covid' variant is 30% more deadly 2021 Data hint B.1.1.7 could be more deadly than thought: TheScientist The World Health Organization. Tracking SARS-CoV-2 variants: The World CoV-2 variant VOC 202012/01 | CDC: CDC Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK Delta plus India: Scientists say too early to tell risk of Covid-19 variant: @BBCWorld Vaccines versus the mutants: TheScientist AstraZeneca says vaccine against new Covid variants may take six months: Guardian; 2021 Pfizer CEO says third Covid vaccine dose likely needed within 12 months Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70 Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera Iran hopes to defeat COVID with home-grown crop of vaccines Ethical approval: Not required.Financial support: No funding was received for writing or publishing this manuscript. Authors have no conflicts of interest to report.